Rahul Jandial, M.D., Ph.D.
Rahul Jandial, M .D., PH.D., is a neurosurgeon and scientist who has been with City of Hope since 2009.
As a surgeon, Dr. Jandial provides complex surgical treatment to patients with cancer. As a scientist, his laboratory investigates the biology of cancer spread (metastasis) to the brain. He has authored 10 books and over 100 academic articles on surgery, neuroscience and cancer biology.
Dr. Jandial graduated from University of California Berkeley, and received his medical doctorate at University of Southern California. He later earned his Ph.D. at UC San Diego, where he also completed his internship and residency in neurosurgery. Prior to joining City of Hope, he completed his oncology fellowship and served as clinical instructor in neurological surgery at UC San Francisco.
American Association of Neurological Surgeons
2008, Doctor of Philosophy, University of California San Diego, La Jolla, CA
2000, Doctor of Medicine, University of Southern California, Los Angeles, CA
1995, B.A., Molecular and Cell Biology, with Honors, University of California Berkeley, Berkeley, CA
2007-2008, Chief Resident, Nuerosurgery
2000-2007, Neurosurgery, University of California San Diego Medical Center, San Diego, CA
2000-2001, Surgery Internship, University of California at San Diego Medical Center, San Diego, CA
2009-present, Associate Professor, Division of Neurosurgery, Department of Surgery, City of Hope, Duarte, CA.
2009-present, Adjunct Assistant Professor, Department of Biology, University of Southern California, Los Angeles, CA
2008-2011, Adjunct Assistant Professor, The Scripps Research Institute, La Jolla, CA
2008, Clinical Instructor, Department of Neurological Surgery, University of California San Francisco, San Francisco, CA
2006-2008, Instructor, Department of Biology, University of California San Diego, San Diego, CA
Understanding the Employment of the Brain Microenvironment by Metastatic Tumor Cells
Brain metastases occur when cancer cells from a primary tumor travel to a distant organ site to form another tumor. Due to the lack of effective treatments and a general deficiency in research into the causes of metastases, the prognosis for patients with brain metastases is poor. One project under investigation is the advantage tumors cells take of the brain microenvironment to improve their ability to survive and establish a metastatic tumor. The brain microenvironment includes the neurotransmitters, neurotrophins, and their associated receptors that can be employed by the metastatic tumor cells. Normally, neurotransmitters and neurotrophins are factors released by brain cells to maintain a balanced brain environment. In our current research in breast cancer brain metastasis, we have found that breast cancer cells that metastasize to the brain express brain-like characteristics, such as GABA and Trk receptors, which were initially thought to be expressed solely on brain cells. We are currently investigating how the breast tumor cells use their own GABA and Trk receptors to increase their metastatic potential in the brain by utilizing the neurotransmitters and neurotrophins provided by the surrounding brain cells.
In addition to the advantage tumor cells take of the brain microenvironment through factors released by brain cells, tumor cells can manipulate the surrounding brain cells, including neural progenitor cells, surrounding the tumor. We have researched the impact of a bone-morphogenic protein on the neural stem cells surrounding the tumor. Our studies show a bidirectional relationship between the tumor cells and the neural stem cells through the release and binding of bone-morphogenic proteins. By understanding the mechanisms metastatic cells use to exploit and manipulate the surrounding brain microenvironment to establish a metastatic tumor, we can increase chances to potentially prevent the formation of brain metastases.
Improving Treatment Options for Brain Tumors and Metastases
Due to the brain’s extreme sensitivity and vital function, patients with primary or metastatic brain cancer have poor prognoses. Current treatments are limited and often futile, since most drugs cannot cross the blood-brain-barrier and greatly diminish patient’s quality of life by killing healthy brain. Therefore, further investigation of BBB permeable drugs with a high affinity to only kill tumor cells is vital. Through collaborations with scientists in the Department of Molecular Medicine, we are investigating the efficacy of a novel chemotherapeutic drug that exploits the tumor cell’s unique metabolism to treat glioblastomas and metastatic brain cancers.
There are two metabolic pathways that cells utilize to multiply and grow: aerobic and anaerobic respiration. Healthy cells rely on aerobic respiration due to its efficient use of nutrients and lack of toxic by-products. But, aerobic respiration requires access to oxygen and thus under oxygen-deficient conditions, cells will rely on anaerobic respiration. Cancer cells are shown to heavily rely on anaerobic respiration even with little available oxygen. One focus in this lab is to utilize this knowledge to develop a treatment which specifically kills the cancer cells and not the healthy brain cells by removing the reliance on anaerobic respiration.
The tumor cell makes an enzyme called glyoxalase I (Glo1) which detoxifies methylglyoxal, a toxic substance produced by the anaerobic pathway. A substance called “GloX1” (discovered at City of Hope) eliminates the ability of Glo1 to detoxify methylglyoxal, thus causing an accumulation of the toxin leading to cell death. By determining the concentration of GloX1 necessary to kill tumor cells with minimal effects on normal brain cells, GloX1 could potentially eliminate the cancer while not harming the healthy brain cells. In addition to preferentially targeting tumor cells, GloX1 shows great promise for future clinical trials since it has been shown to cross the blood-brain-barrier. Therefore, if our lab shows that GloX1 is effective at killing primary or metastatic brain cancer, it would be more implementable in a clinical trial since only simple systemic administration of the drug is required
2019, Sunday Times Bestselling Author - The Sunday Times, London
2019, 2015, Breakthrough Award, Department of Defense
2012, Research Award, ThinkCure!
2010, Excellence Award, City of Hope
2009, NIH Scholar, Oncology Development Award, National Institutes of Health
2009, Cancer Research Award, STOPCancer Foundation
2008, Distinguished Professor Teaching Award, University of California San Diego
2008, Brain Tumor Award, American Brain Tumor Foundation
2008, Research Award, Neurosurgery Research Education Foundation
2007, Community Service Award, American Medical Association
2007, Penfield Research Award, Congress of Neurosurgeons
2006, Excellence in Medicine, American Medical Association
2004, Public Service Award, American Association of Neurological Surgeons
2003, Excellence in Teaching, UCSD - School of Medicine
2000, Dean's Scholar, University of Southern California - School of Medicine
1994, Dean's List, University of California Berkeley
American Association of Neurological Surgeons
American Medical Association
California Medical Association
Congress of Neurological Surgeons
International Neurosurgical Children's Association
San Diego County Medical Society
Society for Neuro-Oncology